ArticleThe Journal of infectious diseases2013
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.
Article in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00391768 (A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir), which is not on this map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) for the Treatment of Children Less Than 24 Months of Age With Confirmed Influenza Infection (CASG 114)
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Pooled it
- Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.The Journal of infectious diseases · 2020Pooled it
- Pharmacokinetics Alterations in Critically Ill Pediatric Patients on Extracorporeal Membrane Oxygenation: A Systematic Review.Frontiers in pediatrics · 2020Pooled it
- Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.The Lancet. Respiratory medicine · 2014Pooled it
- Oseltamivir drug-disease modelling in infants with influenza virus infection.British journal of clinical pharmacology · 2026Article
- Preventing Influenza Virus Infection and Severe Influenza Among Pregnant People and Infants.Journal of women's health (2002) · 2024Article
- Article
- Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.Vaccine · 2023Article
- Using a Physiologically Based Pharmacokinetic Absorption Model to Establish Dissolution Bioequivalence Safe Space for Oseltamivir in Adult and Pediatric Populations.The AAPS journal · 2020Article
- Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Xenotransplantation panel for the detection of infectious agents in pigs.Xenotransplantation · 2018Article
- A travelling camper with a spiking fever, headache, myalgia, hepatitis, and intracellular inclusions.The Lancet. Infectious diseases · 2017Article
- Antiviral Treatments.Clinics in chest medicine · 2017Review
- Pharmacokinetics of oseltamivir in infants under the age of 1 year.Clinical and translational medicine · 2016Article
- Exploiting Genetic Interference for Antiviral Therapy.PLoS genetics · 2016Review
- Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review.Pediatrics · 2015Review
- Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.Advanced drug delivery reviews · 2014Review
- Seasonal Human Influenza: Treatment Options.Current treatment options in infectious diseases · 2014Review
- Antivirals in the 2009 pandemic--lessons and implications for future strategies.Influenza and other respiratory viruses · 2013Review
- Guidance on the use of antiviral drugs for influenza in acute care facilities in Canada, 2014-2015.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicaleArticle
Corrections and comments
- Commented on by
Authors and funding
23 authors at 16 institutions in 1 country.
Funding
Abstract
backgroundChildren <2 years of age are at high risk of influenza-related mortality and morbidity. However, the appropriate dose of oseltamivir for children <2 years of age is unknown.
methodsThe National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group evaluated oseltamivir in infants aged <2 years in an age-de-escalation, adaptive design with a targeted systemic exposure.
resultsFrom 2006 to 2010, 87 subjects enrolled. An oseltamivir dose of 3.0 mg/kg produced drug exposures within the target range in subjects 0-8 months of age, although there was a greater degree of variability in infants <3 months of age. In subjects 9-11 months of age, a dose of 3.5 mg/kg produced drug exposures within the target range. Six of 10 subjects aged 12-23 months receiving the Food and Drug Administration-approved unit dose for this age group (ie, 30 mg) had oseltamivir carboxylate exposures below the target range. Virus from 3 subjects developed oseltamivir resistance during antiviral treatment.
conclusionsThe appropriate twice-daily oral oseltamivir dose for infants ≤8 months of age is 3.0 mg/kg, while the dose for infants 9-11 months old is 3.5 mg/kg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.